Imatinib mesylate ameliorates the dystrophic phenotype in exercised mdx mice
| Autor: | Juliana Caldas Ribeiro, Lilian Cataldi Rodrigues, M. C. R. Costa, Paula Sakemi Fukuhara, Fabíola Attié de Castro, Gislane Lelis Vilela de Oliveira, João C. S. Bizario, Daniel Giuliano Cerri, Auro Nomizo, Daniela Dover de Araújo |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
musculoskeletal diseases medicine.medical_specialty Duchenne muscular dystrophy medicine.medical_treatment Immunology Piperazines Mice Fibrosis Physical Conditioning Animal Internal medicine Animals Immunology and Allergy Medicine Creatine Kinase Protein Kinase Inhibitors biology business.industry Muscles Imatinib Muscular Dystrophy Animal musculoskeletal system medicine.disease Muscular Dystrophy Duchenne Pyrimidines Imatinib mesylate Endocrinology Cytokine Neurology Benzamides Imatinib Mesylate Cancer research biology.protein Cytokines Creatine kinase Neurology (clinical) business Tyrosine kinase Platelet-derived growth factor receptor medicine.drug |
| Zdroj: | Journal of Neuroimmunology. 212:93-101 |
| ISSN: | 0165-5728 |
| Popis: | Myofiber degeneration, inflammation, and fibrosis are remarkable features of Duchenne muscular dystrophy. We hypothesized that the administration of imatinib mesylate, an inhibitor of tyrosine kinase and TGF-beta pro-fibrogenic activity, could improve the muscular conditions in mdx mice. Four-week old mdx mice were treated and exercised for 6 weeks. Gastrocnemius and diaphragm histopathology, strength, creatine kinase, and cytokine levels were evaluated. The treated group presented increased muscular strength and decreased CK levels, injured myofibers, and inflammatory infiltrates. Pro-inflammatory cytokines and TGF-beta were also reduced, while IL-10 was increased, suggesting an immunomodulatory effect of imatinib, which can ameliorate the dystrophic phenotype in mdx mice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect